-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie Seeks FDA Approval for Etentamig to Treat Multiple Myeloma

PUBT·10/27/2026 12:01:54
Listen to the news
AbbVie Seeks FDA Approval for Etentamig to Treat Multiple Myeloma
  • AbbVie submitted a biologics license application to the U.S. FDA for etentamig to treat adults with relapsed or refractory multiple myeloma.
  • The Phase 3 CERVINO trial showed a 60% reduction in progression or death risk versus standard available therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610270800PR_NEWS_USPR_____CG80255) on October 27, 2026, and is solely responsible for the information contained therein.